CellaVision AB
STO:CEVI
EV/EBITDA
Enterprise Value to EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.
Market Cap | EV/EBITDA | ||||
---|---|---|---|---|---|
SE |
CellaVision AB
STO:CEVI
|
6.2B SEK | 33.8 | ||
US |
Abbott Laboratories
NYSE:ABT
|
176.6B USD | 18.5 | ||
US |
Intuitive Surgical Inc
NASDAQ:ISRG
|
141.4B USD | 58.5 | ||
US |
Stryker Corp
NYSE:SYK
|
128.7B USD | 24.8 | ||
US |
Boston Scientific Corp
NYSE:BSX
|
110B USD | 31.3 | ||
IE |
Medtronic PLC
NYSE:MDT
|
106B USD | 13.2 | ||
US |
Becton Dickinson and Co
NYSE:BDX
|
67.4B USD | 17.9 | ||
DE |
Siemens Healthineers AG
XETRA:SHL
|
59.7B EUR | 18.4 | ||
US |
Edwards Lifesciences Corp
NYSE:EW
|
51.7B USD | 26.6 | ||
CN |
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
350.9B CNY | 26.4 | ||
US |
Dexcom Inc
NASDAQ:DXCM
|
46.2B USD | 54 |
EV/EBITDA Forward Multiples
Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.